Donor lymphocyte infusion (DLI) is an option for relapsed hematologic malignancies or incomplete chimerism of non-malignant diseases following allogeneic hematopoietic cell transplantation (HCT). We analyzed the incidence of acute GvHD (aGvHD) in patients treated with DLI. From 1995 to 2013, 171 DLIs were given to 120 patients. The cumulative incidence of post-DLI grade II-IV aGvHD was 33% (CI 25-42%, n = 40; 12 grade II), and of grade III-IV 24% (CI 16-32%, n = 28). GvHD after DLI (n = 46) involved the skin in 70% (n = 32), lower gastrointestinal (GI) 65% (n = 30), upper GI 43% (n = 20) and liver 35% (n = 16). Patients receiving chemotherapy accompanying the DLI (chemo-DLI) (n = 37) had more frequent aGvHD and particularly lower GI GvHD. Risk factors for grade II-IV aGvHD included age 440, chemo-DLI, malignant disease and time from HCT to DLI o200 days. aGvHD response to treatment at 8 weeks was complete in 40% and complete/partial (CR/PR) in 52%. Chemo-DLI had higher response rates to aGVHD treatment in non-CML malignancies. We observed frequent, yet therapy-responsive aGvHD following DLI. GI GvHD in particular is a significant risk when giving chemotherapy prior to DLI. Improvements in DLI efficacy and GvHD management are still needed.
INTRODUCTION
For over 20 years, donor lymphocyte infusion (DLI) has been a therapeutic option for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation (HCT). It is most effective in treatment of relapsed chronic phase CML, with CR rates 470%. 1 DLI has been applied to other hematological malignancies with results falling short of the responses observed for CML. 2, 3 DLI has also been given successfully in non-malignant disorders post HCT for incomplete T-cell chimerism to prevent graft failure. 4 Acute GvHD (aGvHD) causes frequent morbidity and mortality after HCT, with an estimated incidence of 40-50% and subsequent compromised survival. 5 The role of T lymphocytes in perpetuating a GvL effect was suggested when T-cell depleted grafts were reported to yield lower risks of GvHD, yet higher rates of graft failure and relapse. This confirmed the dual role of T cells in maintaining engraftment and directly contributing to antitumor effects. 6 DLI is usually administered without immunosuppression to potentiate a maximal GvL effect. The reported incidence of aGvHD is 40-60% in patients treated with DLI after HCT. 1, 7 We reviewed 171 DLIs in 120 patients at the University of Minnesota (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) to determine the incidence and manifestations of aGvHD.
MATERIALS AND METHODS

Study design
We reviewed the outcome of all patients receiving DLI from February 1995 to October 2013 using the University of Minnesota Blood and Marrow Transplant Database supplemented by detailed review of all available clinical and laboratory records. We identified 120 patients receiving 171 DLIs. Based on active clinical protocols, 37 patients (31%) received immunodepleting chemotherapy prior to DLI (chemo-DLI) for tumor reduction and to permit homeostatic lymphoid expansion of the infused cells. This included fludarabine 25 mg/m 2 i.v. × 5 doses on days − 6 to − 2 and cyclophosphamide 60 mg/kg i.v. for 1 dose on day − 5. 8 All patients receiving DLI were tapered off immunosuppression at least 2 weeks prior to DLI. All patients were followed for a minimum of 1-year post DLI (median 2 years, × range 1-14).
Patients
Patient characteristics (Table 1) include 25 patients with CML, 27 with AML, 12 with myelodysplastic syndrome (MDS), 10 with lymphoma, 4 with acute lymphoid leukemia (ALL), 3 with myeloproliferative disease, 5 with multiple myeloma, 4 with plasma cell leukemia, 3 with Juvenile CML, 2 with CLL, 1 with prolymphocytic leukemia and 1 with renal cell carcinoma. Also, 24 patients with non-malignant disorders included adrenoleukodystrophy, thalassemia, mucupolysaccharidosis I, immunodysregulation polyendocrinopathy enteropathy X-linked syndrome, aplastic anemia, sickle cell anemia, Fanconi anemia, I-cell mucolipidosis, hemophagocytic lymphohistiocytosis and dystrophic epidermolysis bullosa. Indication for DLI in non-malignant disease was incomplete chimerism in the majority of cases. One patient with CML was non-evaluable for aGvHD and excluded from analysis of aGvHD. Six patients who died o1 month after receiving DLI were excluded from analysis of disease response. A total of 113 patients were included in analyses of disease response to DLI and aGvHD. assessments occurred over the first 2-4 weeks post DLI (longer for those receiving chemo-DLI), after which assessments were monthly or when clinically indicated.
Statistical analysis
Data on transplantation patient characteristics, post-transplantation complications and outcomes were prospectively collected by the University of Minnesota Biostatistical Support Group using standardized collection procedures. Patient and transplant characteristics were summarized using descriptive statistics. Statistical comparisons between disease groups used the χ 2 test. All patients were followed longitudinally until death or last follow-up. The cumulative incidence of aGvHD (grades II-IV and III-IV) was calculated using death prior to GvHD as a competing risk. The proportional hazards model of Fine and Gray 8 was used to assess the independent factors of aGvHD (grade II-IV). The factors considered are listed in Table 3 . Kaplan Meier curves were used to estimate OS calculated from time of first DLI until death or last follow-up evaluation. All statistical analyses were performed with Statistical Analysis System statistical software version 9.3 (SAS Institute, Cary, NC, USA).
AGvHD therapy and clinical endpoints
Initial aGvHD treatment included prednisone at 60 mg/m 2 /day (or methylprednisolone IV equivalent) for 14 days followed by taper over 8 weeks for responding patients. Response to treatment of aGvHD was classified at 4 and 8 weeks as either: no response, PR or CR. No response was defined as death prior to the time of evaluation, no improvement or worsening symptoms. CR was defined as complete resolution of aGvHD signs and symptoms in all organs without need for secondary therapy. PR was defined as improvement in GvHD stage in all initially involved organs without development of new organ involvement.
CR of the DLI-treated disease definitions were disease-specific. For CML patients, CR was defined as hematological, cytogenetic or molecular remission. Persistent disease was defined as residual Ph+ cells or evidence of peripheral blood or bone marrow CML. For acute leukemias, CR required o5% marrow blasts, hematologic recovery and absence of any previous cytogenetic abnormality. For myeloma, CR required disappearance of M-protein by electrophoresis and absence of monoclonal marrow plasmacytosis. For lymphoma, CR was defined by clinical resolution by physical exam, imaging and bone marrow examination.
Cause of death was assessed by reviewing death registries and the medical chart and assigned as secondary to disease recurrence, aGvHD, or other. Any infectious cause of death that occurred while on immunosuppression for treatment of aGvHD was classified as a GvHD-related death. DLIs DLI were collected from the donor by steady-state leukapheresis. In all cases, the original allogeneic transplant donor was used for DLI. Infused doses ranged from 4.7 × 10 5 to 2.29 × 10 8 CD3+ cells/kg. Median single DLI dose was 5 × 10 7 CD3+ cells/kg and median total DLI dose was 6.7 × 10 7 CD3+ cells/kg. Multiple DLI infusions were given × 2 (n = 33 patients), × 3 (n = 21), × 4 (n = 6), × 5 (n = 3) and × 6 (n = 1). Patients with either malignant or non-malignant diseases received multiple DLIs. For patients receiving multiple DLIs, the total cell dose was used for analysis of outcomes. Dose selections were based on availability of donor lymphocyte collection and contemporary treatment protocols.
RESULTS
The patients' clinical characteristics are shown in Table 1 and included 120 patients; 79% (n = 96) treated for relapsed Total N  120  25  31  12  10  18 24
Year of DLI 1990-1999
Other malignancies include myeloproliferative disease (n = 3), multiple myeloma (n = 5), plasma cell leukemia (n = 4), juvenile CML (n = 3), chronic lymphocytic leukemia (n = 2), prolymphocytic leukemia (n = 1) and renal cell carcinoma (n = 1).
GvHD after DLI
hematological malignancy and 21% (n = 24) for non-malignant conditions. The largest disease subgroups were CML (n = 25) and AML (n = 27). The median age at time of DLI was 36 years (range, 9 months-66 years). The group included more males (57%) than females. Thirty-seven (31%) patients received lymphodepleting chemotherapy immediately prior to DLI, half in the AML subgroup (n = 19). Eighty-three donors (69%) were HLA-matched siblings and 37 (31%) unrelated donors. Most DLIs were performed4200 days after HCT (median 255, range 29-8536 days); only 26 were given beyond 3 years post HCT.
Incidence and clinical manifestations of aGvHD In 120 patients, 46 developed aGvHD grade I-IV at a median of 34 days (range, 5-121 days) after the first DLI infusion. The cumulative incidence of grade II-IV aGvHD was 33% (95% confidence interval (CI) 25-42%) (n = 40) and grade III-IV aGvHD 24% (95% CI 16-32%) (n = 28). GvHD organ involvement is shown in Table 2 . The maximum GvHD grade was grade I in 13% (n = 6), grade II in 26% (n = 12), grade III in 28% (n = 13) and grade IV in 33% (n = 15). Of those receiving DLI, skin aGvHD developed in 70% (n = 32), lower gastrointestinal (GI) in 65% (n = 30), upper GI in 44% (n = 20) and liver in 35% (n = 16). Chemo-DLI recipients (n = 37) had significantly higher rates of aGvHD II-IV than DLI without chemotherapy (59% vs 22%, P o0.01). Patients receiving chemo-DLI had similar rates of liver and upper GI aGvHD, but more frequent lower GI aGvHD (51% vs 13%).
Chronic GvHD after DLI was observed in 24% (29/120). Forty-six patients survived free of chronic GvHD for 41 year. Eighteen patients had both acute and chronic GvHD, while 11 had chronic GvHD only.
Risk factors for aGvHD
Risk factors for Gr II-IV aGVHD are shown in Table 3 and analyzed both as a whole and separately in CML, non-CML malignancy and non-malignancy subgroups. Age 4 40 (P o0.01), chemo-DLI (P o 0.01) and o 200 days from BMT to DLI (P = 0.01) were associated with significantly higher risks of grade II-IV aGVHD in the total group. Patients with CML were less likely to have aGVHD compared to non-CML malignancies and non-malignancies (P o 0.01). In all 67% of the total DLI doses were 45 × 10 7 CD3+ cells/kg and higher total DLI doses trended towards a higher aGVHD risk in the total group (P = 0.07). A prior history of aGVHD led to slightly more frequent aGVHD after DLI, but was not significant (P = 0.32).
In the CML subgroup, 6 of 24 (25%) patients developed aGVHD of any grade and 4 of 24 (17%) developed grade II-IV aGVHD. There was a stronger correlation of prior aGVHD with aGVHD after DLI (P = 0.06). Chronic-phase CML was associated with more frequent aGVHD compared to accelerated phase (50% vs 12%, P = 0.02), and this remained significant when adjusted for chemo-DLI (P = 0.05). This may be reflective of more chronic-phase transplants that were performed in the pre-tyrosine kinase inhibitor era with less effective GVHD prophylaxis. Prior chronic GVHD, chemo-DLI and total DLI dose were not significant risk factors for aGVHD.
In non-CML malignancies, 33 of 71 (46%) patients developed aGVHD. Chemo-DLI was a significant risk factor for aGVHD (62% vs 27%, P o0.01). Prior acute or chronic GVHD, DLI dose, and disease status at DLI were not significantly associated with aGVHD.
In non-malignancies, 6 of 24 (25%) patients developed aGVHD. Prior acute or chronic GVHD and DLI dose were not associated with aGVHD.
Response to treatment of aGvHD Of 44 evaluable patients treated for aGvHD after DLI, 6 died within 4 weeks and thus were not evaluable for response; 3 of them had GvHD as a cause of death (Table 4 ). Of 40 patients with grade II-IV aGvHD, 28% (n = 11) achieved a CR and 55% (n = 22) had a CR/PR at 4 weeks. The overall response rate at 4 weeks is similar to that described for aGvHD after HCT (64% CR/PR) where most patients had a CR (49%) in contrast with the lower CR rate we observed post DLI. 10 At 8 weeks, CR was observed in 40% (n = 16) and CR/PR in 52% (n = 21). At 8 weeks, 10% (n = 4) had no response and 35% (n = 14) of patients had died. Treatment responses for grade II-IV and III-IV aGvHD were similar. At 8 weeks, liver GvHD responded poorly (only 25% CR/PR, n = 16) while patients with skin or GI involvement had 45-59% CR/PR. Age, malignancy, time from HCT to DLI, time from DLI to aGvHD, donor type, chemo-DLI and the infused DLI dose did not influence the efficacy of aGvHD treatment. In the CML subgroup ( Supplementary Table 1a ), there were no significant factors that predicted good response to aGVHD outcome, but in non-CML malignancies ( Supplementary Table  1b ), chemo-DLI was associated with a good response to treatment, as 73% vs 36% had CR/PR (P = 0.05) at 4 weeks and 64% vs 27% had CR/PR at 8 weeks (P = 0.05) with chemo-DLI vs without. Additionally, in non-CML malignancies, a higher largest single dose of donor lymphocytes predicted improved CR + PR rates at 4 weeks (P = 0.03) and 8 weeks (P = 0.03) compared to NR/death and a higher total dose of donor lymphocytes improved CR + PR rates at 8 weeks (P = 0.02) compared to NR/death. There were no significant predictors for aGVHD response to treatment in the non-malignant group ( Supplementary Table 1c ).
Disease response and survival after DLI CR after DLI was achieved in 54% (48/89) of all patients with malignancies ( Figure 1 ). In CML (n = 25), CR was 80% (20/25) with most treatment failure in patients with accelerated phase disease. In non-CML malignancies (n = 65), rates of CR ranged from 25 to 55% for disease subgroups with overall similar CR at 45 and 46% for chemo-DLI and non-chemo DLI, respectively. However, higher CR rates with chemo-DLI were reported in lymphoma (28% CR with chemo-DLI vs 0% without, n = 7).
The development of aGvHD influenced the success in achieving CR in non-CML malignancies. Patients with aGvHD after DLI had higher CR rates. Only 9% (6/71) of patients had CR after DLI without aGVHD of any grade. CR rate for malignant disease overall was 73% (22/30) with aGVHD and 44% (26/59) without. In acute leukemias (AML + ALL), CR rate was high (8/11, 73%) with aGVHD and low (6/18, 33%) without. In lymphoma, CR rate was low both with aGVHD (1/5, 25%) and without (1/6, 17%). In other malignancies, CR rate was high with aGVHD (8/9, 89%) and low without (5/17, 29%) . Of seven patients with non-CML malignancies who had no response to GVHD treatment at 4 weeks, four of seven did have a response of their malignant disease. This was not true of CML as CR rate was 83% with or without aGVHD (5/6 with Survival was significantly increased in patients without or with mild aGvHD (41% vs 22%).
GvHD after DLI aGVHD, 15/18 without aGVHD). One patient did not have aGVHD data available and thus was excluded from CR/aGVHD analysis. Among patients with non-malignant diseases, 79% (19/24) survive 41 year post DLI with follow-up between 1 and 14 years. Of five deaths, four patients had developed aGvHD. Causes of death included three from aGvHD, one from infection and one from secondary B-cell lymphoma. Only 1 of 19 of surviving patients developed aGvHD. DLI was successful in attaining complete engraftment as only 3 out of 24 patients failed to engraft.
OS at 2 years for patients with CML was similar (83% vs 79%) with or without aGvHD (Figure 2a ). However, for non-CML malignancies, OS at 2 years was significantly better without aGvHD at 41% vs 22% (Figure 2b) .
Of patients who died without post-DLI malignant relapse (n = 25), the median time from DLI to death was 4 months. Only 25% survived at 1 year and 12% at 2 years. Of patients who achieved CR after DLI (n = 41), survival at 2 years was 51%; 88% for those with CML and 25% for non-CML malignancies.
DISCUSSION
In this large consecutive series of patients receiving DLI, the cumulative incidence of grade II-IV and III-IV aGvHD was 33 and 24%, respectively, similar though somewhat lower than earlier reports describing 41-46% aGvHD after DLI 1,4 and 37-63% after allogeneic HCT. 10, 11 The chemo-DLI subgroup had more frequent, advanced grade aGvHD, particularly with lower GI involvement. The toxic and pro-inflammatory effects of chemotherapy on the GI mucosa may have contributed to this higher incidence of GI GvHD. We attempted amelioration in part by infusion of lower cell doses of DLI after the preceding chemotherapy; our earlier report noted 25% vs 66% aGvHD with the lower cell dose chemo-DLI 12 while achieving high rates of disease response using chemo-DLI. However, our current analysis does not support a direct relationship between DLI cell dose and development of aGvHD.
In comparison with post-HCT GvHD, aGvHD after DLI appears to have more frequent organ involvement, particularly upper and lower GI and liver at time of initiation of therapy. 5, 6, 10 The frequency and severity of liver, upper GI and lower GI GvHD were higher after DLI compared with a large series (n = 1723) of patients with aGvHD after HCT described by MacMillan et al. 13 The post-HCT incidence of lower GI GvHD was similar at 65%, but Gr III-IV GI GvHD comprised 26% of total GI GvHD vs 73% in our study of post-DLI GvHD. We did not observe the hepatitic variant of liver aGvHD after DLI. 14 Higher rates of aGvHD are likely a result of withholding immunosuppressive medications at the time of DLI administration in effort to induce maximum graft-versus-tumor effect.
Importantly, we noted that treatment of aGvHD after DLI yielded similar overall response rates to aGvHD following HCT. We observed CR/PR rates of 55% at 4 weeks and 53% at 8 weeks. This is similar to response rates after HCT, but was more frequently a PR rather than CR. Liver GvHD was associated with the lowest response rates to treatment which likely reflects high morbidity associated with derangement in liver function. Chemo-DLI was associated with more aGVHD in non-CML malignancies, but the GVHD was still responsive as it had higher overall response rates to treatment.
We observed a correlation between disease remission and aGvHD in post-DLI patients, except in those with CML who had frequent responses, even without GvHD. In an early multicenter analysis, Collins et al. reported that 93% of complete responders had aGvHD, while only 13% of those without acute or chronic GvHD achieved CR. 3 Kolb et al. 1 reported durable remissions in chronic phase CML and a correlation of response with aGvHD (91% responses with GvHD vs 45% without).
The relationship of aGvHD to disease response was most notable in the cohort with acute leukemias and other malignancies including plasma cell disorders. CML patients responded with or without aGvHD, possibly reflecting the bcr-abl fusion protein acting as a leukemia-specific antigenic target. However, of 71 non-CML patients without aGvHD, only 6 had a disease response. In contrast to some series, the development of aGvHD and an associated remission did not translate into increased 2-year survival, either in CML or non-CML malignancies. 15 Whether some GvHD is permissive for a maximal graft-versustumor effect has been debated. Some groups have administered interferon-alpha to promote GvHD in hopes of improving disease response. 16, 17 DLI has been given along with chemotherapy and concurrent immunosuppression to reduce GvHD rates. Using this approach, Yan et al. reported higher CR rates compared with chemotherapy alone, suggesting that despite the post-DLI immunosuppression, the GvL effect was still clinically evident. Modified DLI techniques have been explored to maximize GvL while minimizing GvHD including ex vivo T-cell activation with dose escalation 18 and transduction of suicide genes to lymphocytes to selectively control GvHD. 19 TCR transfer of donor lymphocytes may also enhance the specificity of antigen recognition and thus augment GvL while reducing GvHD. 20 The clinical value and reproducibility of these techniques in vivo remain uncertain.
Our analysis did show that about half of patients with aGvHD had persisting GvHD at 4 weeks despite treatment, yet had CR of their disease. Pre-DLI chemotherapy might contribute to tumor cell eradication, but also to depletion of immunosuppressive regulatory elements such as regulatory T cells or myeloid-derived suppressor cells. This suggests the presence of complex immunologic interactions that remain incompletely understood and not well regulated by current clinical interventions. These interactions need further study to improve clinical safety and antitumor responses.
Chronic GvHD after DLI has been previously shown to be positively associated with improved survival in relapsed acute leukemia 21 and with no impact on mortality in a large multicenter study of CML. 22 As both acute and chronic GvHD are a significant risk following DLI, optimal treatment to improve both survival and quality of life is still an active area of investigation.
We identified some subgroups at particularly high risk for aGvHD following DLI, including older patients, those receiving chemo-DLI and DLI given soon (o 200 days) after HCT. Whether these groups require different management remains a question for future studies. Prior acute or chronic GvHD did not significantly influence the risk for developing aGvHD, so DLI should be not be withheld due to history of GvHD if it has resolved. Other comorbidities besides chemotherapy exposure may also play a role in the development of aGvHD, although it is not clear how such comorbidities may contribute to the outcomes of DLI. 23 The development of tyrosine kinase inhibitors for moleculartargeted treatment of CML has markedly reduced the need for HCT for CML. In the 2010 EBMT survey, 62% of allogeneic HCTs were performed for AML, ALL and MDS/MPS: only 3% for CML. 24 In addition, tyrosine kinase inhibitors or other targeted therapy may supplant the need for DLI for CML patients who relapse after HCT. Such effective targeted therapies are not available for patients with non-CML hematologic malignancies. As a result, DLI remains an important component of contemporary post-HCT relapse therapy. New methods of enhancing responses while allowing time for the development of GvL, possibly including the use of DLI in combination with molecularly targeted therapies, may further improve outcomes. Alternatively, direct enhancement of donorderived antitumor activity using immunostimulatory cytokines (e.g. IL-2 or IL-15) or through inhibition of immune checkpoints (with anti-CTLA4 or anti-PD1/PDL1) might be of value, though potentially augmenting risks of GvHD. Although we observed that aGvHD after DLI was associated with disease response, it ultimately compromised survival. Therefore, future efforts should also focus on minimizing GvHD, particularly visceral GvHD, after DLI.
